Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | AHR | P35869 | 2/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | CCR8 | P51685 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.40 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL946635 | 1.00 | SMN1; SMN2 (0.67) | SMN1; SMN2L3MBTL1AHRCHRM2BLM | |
| SCHEMBL6921056 | 0.86 | SMN1; SMN2 (0.67) | SMN1; SMN2L3MBTL1AHRCHRM2BLM | |
| SCHEMBL12717303 | 0.86 | SMN1; SMN2 (0.67) | SMN1; SMN2L3MBTL1AHRCHRM2BLM | |
| SCHEMBL4388586 | 0.86 | SMN1; SMN2 (0.67) | SMN1; SMN2L3MBTL1AHRCHRM2BLM | |
| SCHEMBL27997203 | 0.84 | SMN1; SMN2 (0.64) | SMN1; SMN2L3MBTL1AHRCHRM2BLM | |
| SCHEMBL10442032 | 0.82 | SMN1; SMN2 (0.61) | SMN1; SMN2L3MBTL1AHRCHRM2BLM | |
| SCHEMBL21742008 | 0.82 | SMN1; SMN2 (0.61) | SMN1; SMN2L3MBTL1AHRCHRM2BLM | |
| SCHEMBL16230664 | 0.82 | SMN1; SMN2 (0.61) | SMN1; SMN2L3MBTL1AHRCHRM2BLM | |
| SCHEMBL17490343 | 0.81 | SMN1; SMN2 (0.55) | SMN1; SMN2L3MBTL1AHRCHRM2BLM | |
| SCHEMBL21883522 | 0.81 | L3MBTL1 (0.55) | SMN1; SMN2L3MBTL1AHRCHRM2BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042772-A1 | FURO PYRIMIDINE DERIVATES | MERCK PATENT GMBH (DE) | 2026-02-12 | — | — | US | claimed |
| CN-122050562-A | Analysis method for cascade cyclization reaction mechanism of pyridyl Gao Guibing alcohol and propargyl alcohol catalyzed by bimetallic system | 南昌航空大学 | 2026-05-15 | — | — | CN | disclosed |
| EP-4709720-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12441725-B2 | ISO-citrate dehydrogenase (IDH) inhibitor | ZHEJIANG METON PHARMACEUTICAL CO., LTD (CN) | 2025-10-14 | — | — | US | disclosed |
| WO-2024233846-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | LARKSPUR BIOSCIENCES, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| CN-118786128-A | Compounds and methods for treating viral infections | 吉利德科学公司 | 2024-10-15 | — | — | CN | disclosed |
| US-20240116917-A1 | ISO-CITRATE DEHYDROGENASE (IDH) INHIBITOR | ZHEJIANG METON PHARMACEUTICAL CO., LTD (CN) | 2024-04-11 | — | — | US | disclosed |
| EP-4313373-A1 | CATALYSTS AND METHODS FOR THE HYDRATION AND ABSORPTION OF CARBON DIOXIDE | Air Company Holdings, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-4139293-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2023-03-01 | — | — | EP | disclosed |
| WO-2023280254-A1 | TEAD INHIBITOR | 武汉人福创新药物研发中心有限公司 | 2023-01-12 | — | — | WO | disclosed |
| WO-2022204233-A1 | CATALYSTS AND METHODS FOR THE HYDRATION AND ABSORPTION OF CARBON DIOXIDE | AIR COMPANY HOLDINGS, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116917-A1 | ISO-CITRATE DEHYDROGENASE (IDH) INHIBITOR | IDH2, IDH3A, IDH1 | SMN1; SMN2 3453/4885L3MBTL1 3273/4885AHR 1535/4885 |
| US-12441725-B2 | ISO-citrate dehydrogenase (IDH) inhibitor | IDH2, IDH3A, IDH1 | SMN1; SMN2 3453/4885L3MBTL1 3273/4885AHR 1535/4885 |
| US-20260042772-A1 | FURO PYRIMIDINE DERIVATES | HAVCR2, CYC1, CNKSR1 | SMN1; SMN2 4310/4885L3MBTL1 2090/4885AHR 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.